TScan Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- TScan Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2836 — Biological Products, (No Diagnostic Substances)
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Waltham
- Headquarters state / province
- Massachusetts
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- TCRX
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001783328
- EIN
- 82-5282075
Board of directors
-
Barbara Klencke · DirectorSince 2023
-
David P. Southwell · Director · Chief Executive OfficerSince 2023
- Since 2023
-
Gabriela Gruia · DirectorSince 2023
-
Garry A. Nicholson · DirectorSince 2024
-
Gavin MacBeath · Director · Chief Executive OfficerSince 2023
- Since 2023
-
Katina Dorton · DirectorSince 2023
-
Keith Woods · DirectorSince 2023
-
Timothy J. Barberich · DirectorSince 2023
Chief executives
David P. Southwell
· Chief Executive Officer
Dates unknown
Gavin MacBeath
· Chief Executive Officer
Dates unknown
Director election results
Annual meeting of May 20, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
81.4%
Board connections
8 of this board's directors also sit on 23 other boards.
- via Felix Baker, Julian Baker and Keith Woods
- via Felix Baker, Julian Baker and Katina Dorton
- via Felix Baker and Julian Baker
- via Felix Baker and Julian Baker
- via Felix Baker and Julian Baker
- via Felix Baker and Julian Baker
- via Felix Baker and Julian Baker
- via Felix Baker and Julian Baker
- via Felix Baker and Julian Baker
- via Felix Baker and Julian Baker
- via Felix Baker and Julian Baker
- via Felix Baker and Julian Baker
- via Felix Baker and Julian Baker
- via Felix Baker and Julian Baker
- via David P. Southwell and Keith Woods
- via Felix Baker and Julian Baker
- via Barbara Klencke
- via Gabriela Gruia
- via Katina Dorton
- via Garry A. Nicholson
- via David P. Southwell
- via Keith Woods
- via Barbara Klencke
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $145,621
- 3 purchases by 1 insider
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Dec 23, 2025 | Lynx1 Capital Management LP 10% owner | Open-market purchase | +6,232 | $0.90 | $5,609 |
| Dec 22, 2025 | Lynx1 Capital Management LP 10% owner | Open-market purchase | +75,500 | $0.90 | $67,950 |
| Dec 19, 2025 | Lynx1 Capital Management LP 10% owner | Open-market purchase | +80,069 | $0.90 | $72,062 |
| May 20, 2025 | Lynx1 Capital Management LP 10% owner | Open-market purchase | +1,200,000 | $1.20 | $1,440,000 |
| May 19, 2025 | Lynx1 Capital Management LP 10% owner | Open-market purchase | +1,388,794 | $1.20 | $1,666,553 |
| Dec 13, 2024 | Nichols Weston 10% owner | Open-market purchase | +100,000 | $2.90 | $290,000 |
| Dec 12, 2024 | Nichols Weston 10% owner | Open-market purchase | +31,800 | $3.01 | $95,718 |
| Nov 15, 2024 | Nichols Weston 10% owner | Open-market purchase | +947 | $4.34 | $4,110 |
| Sep 23, 2024 | Barbara Klencke Director | Open-market purchase | +5,000 | $5.29 | $26,450 |
| Aug 26, 2024 | Barbara Klencke Director | Open-market purchase | +5,000 | $5.53 | $27,650 |
| Aug 23, 2024 | Barbara Klencke Director | Open-market purchase | +5,000 | $5.69 | $28,450 |
| Aug 23, 2024 | ZDRAVESKI ZORAN Officer (See Remarks) | Option exercise | +54,895 | $4.85 | $266,241 |
| Aug 23, 2024 | ZDRAVESKI ZORAN Officer (See Remarks) | Option exercise | +25,000 | $3.27 | $81,750 |
| Aug 23, 2024 | ZDRAVESKI ZORAN Officer (See Remarks) | Option exercise | +13,125 | $1.81 | $23,756 |
| Aug 23, 2024 | ZDRAVESKI ZORAN Officer (See Remarks) | Option exercise | +64,166 | $2.49 | $159,773 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.